Headache Medicine C-Cert Learning Objectives and CME

C-cert Activity Description

The Continuous Certification (C-cert) activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty. The annual activities include: 1) reading the subspecialty Reading List of journal articles, and 2) taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content. 

Learning Objectives

Upon completion of this UCNS C-cert activity, participants will be able to:
  • More accurately identify primary and secondary headaches
  • Incorporate new acute migraine treatments into practice
  • Incorporate new preventive migraine treatments into practice

Core Competencies

This UCNS C-cert activity covers the following core competency:
  • Medical Knowledge

AMA Credit Designation Statement

The American Academy of Neurology Institute designates this enduring material for a maximum of 11 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Medical Education (CME) Instructions

To claim CME credits, answer question 26 on the quiz to reflect the total time spent completing the required reading and online quiz. This question is not included in the scoring of the quiz. A passing score of 80% of higher is needed to meet C-cert requirements and receive CME credit. CME credit confirmation will be emailed within ten business days of passing the quiz.

ACCME Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Neurology Institute (AANI) and United Council for Neurologic Subspecialties. The AANI is accredited by the ACCME to provide continuing medical education for physicians.

Disclosures

The UCNS complies with all standards and policies of the ACCME, including identification and resolution of all conflicts of interest prior to the educational activity being delivered to learners. Accordingly, UCNS  planners, authors, and staff comply with the UCNS’s Conflicts of Interest Policy

Headache Medicine Certification Examination Committee Contributors

James R. Couch, MD, PhD, FAAN, Chair, University of Oklahoma Health Sciences Center
Disclosures: Receives speaker compensation to serve on speaker's bureau for Allergan Co. for their new migraine treatment and from Ubrogepant for a speaking engagement.

Randolph Evans, MD, Houston Methodist
Disclosures: Receives speaker fees for being member of speaker's bureaus for Allergan, Amgen, Biohaven, Novartis, and Teva.

Alan G. Finkel, MD, FAAN, FAHS, Carolina Headache Institute
Disclosures: Member of Allergan Scientific Advisory Board and receives speaker fees; Receives speaker fees from Amgen. Consultant for Biohaven; and member of  Theranica Scientific Advisory Board.

Deborah I. Friedman, MD, FAAN, UT Southwestern Medical Center
Disclosures: Receives compensation for being member of advisory boards for Alder/Lundbeck, Amgen/Novartis, Biohaven Pharmaceuticals, Eli Lilly, Impel, Revance, Supernus, Teva, Theranica, MedLink Neurology, and Zosano. Consultant to electroCore. Receives compensation as Contributing Author for Medscape and contributing author and Editorial Board for Neurology Reviews.  Received research support for clinical trials from Allergan, Autonomic Technologies, and Zasano (company filed for insolvency April 2019). Clinical research funding received from Merck (investigator initiated).

Robert Kaniecki, The Headache Center
Disclosures: Nothing to disclose.

Christine Lay, MD, Women's College Hospital
Disclosures: Receives speaker's bureau fees from Aralez, Novartis; Member of advisory boards for Allergan, Lilly, Novartis, and Aralez. Fees are paid directly to the physician’s institution.

Jerry Swanson, MD, Mayo Clinic – Rochester
Disclosures: Receives royalty payments from UpToDate for editorial services.

Stewart J. Tepper, MD, Dartmouth College
Disclosures: Receives honoraria as a Consultant and/or Advisory Board member for  Acorda, Alder, Alexsa, Align Strategies, Allergan, Alphasights, Amgen, Aperture Venture Partners, Aralez Pharmaceuticals Canada, Axsome Therapeutics, Becker Pharmaceutical Consulting, BioDelivery Sciences International, Biohaven, Charleston Labs, Currax, Decision Resources, DeepBench, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Equinox, ExpertConnect, GLG, GSK, Guidepoint Global, Impel, M3 Global Research, Magellan Rx Management, Marcia Berenson Connected Research and Consulting, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pfizer, Pulmatrix, Reckner Healthcare, Relevale, Revance, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Spherix Global Insights, Sudler and Hennessey, Synapse Medical Communications, Teva, Theranica, Thought Leader Select, Trinity Partners, XOC, and Zosano. Receives salary from Dartmouth-Hitchcock Medical Center and American Headache Society. Received stock options from Percept and CME honoraria from  American Academy of Neurology, American Headache Society, Cleveland Clinic Foundation, Diamond Headache Clinic, Elsevier, Forefront Collaborative, Hamilton General Hospital, Ontario, Canada, Henry Ford Hospital, Detroit, Inova, Headache Cooperative of New England, Medical Learning Institute Peerview, Miller Medical Communications, Physicians’ Education Resource, Rockpointe, and WebMD/Medscape. Receives research grants from Alder, Allergan, Amgen, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Neurolief, Novartis, Scion Neurostim, Teva, and Zosano.

Paul Winner, DO, FAAN, Palm Beach Headache Center
Disclosures: Receives compensation from the following companies for speaker and/or advisory board fees: Allergan, speaker fees and consultant on advisory board; Amgen for speaker fees and consultant on advisory board; Lundbeck/Alder: speaker fees and consultant on advisory board; Novartis: speaker and consultant on advisory board; Biohaven: Speaker and consultant on advisory board;  Supernus: speaker and consultant on advisory board. 
Receives clinical research funding support from Allergan, Amgen, Lundbeck/Alder Biohaven, and Novartis. Receives research funding from Biogen for clinical research relating to dementia and from Novartis for multiple sclerosis.

 

Staff Contact

Todd Bulson, Senior Manager Certification
tbulson@ucns.org
(612) 928-6067

Becky Swanson, Operations and Executive Office Manager
bswanson@ucns.org
(612) 928-6050